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Objectives and design: fucoidan has previously been shown to inhibit the proliferation of arterial smooth muscle cells
both in animal models and in vitro. However, the mechanisms behind the anti-proliferative effects of this polysulfated
polysaccharide are not known in detail. Here, the inhibitory effect of fucoidan on rat aortic smooth muscle cell proliferation
was examined and compared with the effects of heparin after stimulation with fetal calf serum, platelet-derived growth
factor BB, basic fibroblast growth factor, heparin-binding epidermal growth factor, and angiotensin II.
Materials and methods: the cultures were analysed with respect to cell proliferation and DNA synthesis by cell counting
and measurement of 3H-thymidine incorporation. Phosphorylation of mitogen-activated protein kinase and nuclear
translocation of phosphorylated mitogen-activated protein kinase were studied by immunoblotting and immuno-
cytochemistry.
Results: fucoidan was shown to be a more potent inhibitor of smooth muscle cell proliferation than heparin. Fucoidan
also reduced growth factor-induced activation of mitogen-activated protein kinase and prevented nuclear translocation of
phosphorylated mitogen-activated protein kinase.
Conclusion: fucoidan is a more potent anti-proliferative polysulphated polysaccharide than heparin and may mediate its
effects through inhibition of the mitogen-activated protein kinase pathway in a similar manner as heparin.
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Introduction factors have been implicated in autocrine growth con-
trol.5–7 Although knowledge of the mechanisms that
control SMC function has increased, effective therapyVascular remodelling occurs during atherogenesis,
against SMC proliferation in atherogenesis, restenosispost-angioplasty restenosis, and chronic rejection of
and transplant vascular disease is still lacking.transplanted organs. Intimal hyperplasia is one of
SMC function is modulated by heparin both in vivomany components involved in vascular remodelling
and in vitro.8,9 Heparin binds to protease-sensitiveand smooth muscle cell (SMC) proliferation is a key
binding sites on SMCs and has been suggested to enterfactor in this process. After activation, SMCs migrate
the cells by receptor-mediated endocytosis.10 Heparinto the intima, proliferate, and secrete extracellular
inhibits the induction of matrix metalloproteinasesmatrix components.1–4
and, by interaction with extracellular proteins, it modi-In animal models, various growth factors have been
fies cell-matrix interactions and influences cell mi-shown to influence the development of intimal hy-
gration.11–13 The mechanisms responsible for the anti-perplasia. Platelet-derived growth factor BB (PDGF-
proliferative effects of heparin are not known in detail.BB) is a potent mitogen and chemoattractant for SMCs
Heparin prevents cell cycle progression,14,15 suppressesand basic fibroblast growth factor (bFGF) promotes
induction of activator protein-1 (AP-1)/c-fos andSMC proliferation and re-endothelialisation in injured
c-jun,16 and inhibits activation of PKC.17 Mitogen-ac-vessels. SMC proliferation is also controlled by an-
tivated protein kinase (MAPK) is an important trans-giotensin II (AT II) and a number of other growth
mitter of growth factor-related signals from both
tyrosine kinase receptors and G-protein associated
receptors.18 MAPK includes extracellular signal-reg-
∗ Please address all correspondence to: U. Hedin, Department of
ulated kinase (ERK), which is dependent on cell ac-Surgical Sciences, Division of Vascular Surgery, Karolinska Hospital,
SE-171 76 Stockholm, Sweden. tivation by growth factors and regulates cell growth
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and differentiation. Other MAPKs are c-Jun N-terminal cell cultures were maintained in F-12 medium (Gibco
Life Technologies, Grand Island, NY, U.S.A.) sup-kinase (JNK) and p38 MAPK, which function mainly
in stress responses, apoptosis and inflammation.19,20 plemented with 10% fetal calf serum (FCS), 200 U/
ml penicillin, 0.2 mg/ml streptomycin, and 50 g/mlRecently, the growth inhibitory properties of heparin
were shown to be associated with inhibition of growth ascorbic acid (F12/FCS). They were incubated at 37 °C
in 5% CO2 in air and used in passage 3 to 8. Confluentfactor-induced ERK activation in SMCs.21–24
Fucoidan is also a potent inhibitor of SMC growth cell cultures were detached with 0.1% trypsin and
0.02% EDTA and seeded at 2×104 cells/cm2 in F12/in vivo and in vitro.25 It is a polyanionic, sulfated
polymer of L-fucose obtained from brown marine FCS. After 24 h of culture, the cells were shifted to F-
12 medium supplemented with 0.1% BSA and growth-algae and has an anticoagulant activity lower than
that of heparin.26 The mechanism by which fucoidan arrested for 72 h. To determine the effects of fucoidan
or heparin on SMC proliferation, cells were plated atexerts its anti-proliferative action is not known. It has
been proposed to bind to growth factors27 and to alter low density (5×103/well) and cultured in F12/FCS
for 48–96–144 h in the presence or absence of 100 g/the expression of fibronectin, thrombospondin,28 and
collagen.29 Its inhibitory activity depends on molecular ml fucoidan or heparin. Cell number was counted
using an automatic cell counter and net growth wasweight30 and, like heparin, fucoidan binds to the cell
surface and is degraded by SMCs.30 determined.
The purpose of this study was to investigate how
fucoidan modulates SMC proliferation induced by MAPK assay
different growth factors and to find out if it interferes
with MAPK/ERK signalling pathways in a similar SMCs grown in 60 mm Petri dishes were serum-
manner to heparin. starved for 72 h. The cells were then stimulated with
growth factors in the presence or absence of heparin
or fucoidan for different time intervals, lysed on ice
for 10 min in SDS sample buffer (62.5 mM Tris-HCl,
Materials and Methods pH 6.8), 2% SDS, 10% glycerol, 50 mM DTT, 0.1%
bromophenol blue), scraped off the dishes and cent-Mouse monoclonal antibodies (pMAPKm) and rabbit rifuged for 10 min at 103 rpm. The samples were heatedpolyclonal antibodies (pMAPKp) against phos- to 100 °C for 10 min, cooled on ice and centrifuged. Aphorylated p42/44 (phosphoMAPK) were purchased 20 l aliquot of each sample was loaded onto 10% SDS-from Bio Labs (Beverly, MA, U.S.A.). Rabbit polyclonal PAGE gels (Bio-RAD mini gel system) and, followingMAPK antibodies were a gift from R. Seger.31 Porcine electrophoresis, the proteins were transferred tomucosa heparin, fucoidan from Fucus vesiculosus, bo- Hybond-C nitrocellulose membrane (Amersham,vine serum albumin (BSA), human AT II, and human Buckinghamshire, U.K.). The membrane was washedPDGF-BB were purchased from Sigma (St. Louis, MO, with 50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 0.05%U.S.A.). Fluorescein isothiocyanate (FITC)-conjugated Tween (TTBS) and incubated in blocking buffer (3%porcine anti-rabbit Fab’ fragment, alkaline phos- BSA in TTBS) for 1 h. The membrane was thereafterphatase conjugated goat anti-rabbit IgG (AP anti- incubated with pMAPKm or pMAPKp antibodies (di-bodies) were purchased from Dako (Glostrup, luted 1:2000 or 1:1000, respectively) in TTBS with 0.1%Denmark). Prestained SDS-PAGE size markers and BSA with agitation overnight at 4 °C. The membranealkaline phosphatase substrate were purchased from was then washed three times with TTBS and incubatedBio-Rad (Richmond, CA, U.S.A.). Biotinylated goat with biotinylated goat antibody and developed withanti-mouse IgG and Vectastain Elite ABC Kit were Vectastain Elite ABC Kit or with AP secondary anti-purchased from Vector Laboratories (Burlingame, CA, bodies and detected with AP substrate (BioRad). ToU.S.A.). Human basic FGF (bFGF) and human heparin- estimate loaded amount of MAPK protein, the mem-binding epidermal growth factor (hbEGF) were ob- branes were also incubated with MAPK antibodiestained from R&D Systems (Minneapolis, MN, U.S.A.). (1:1000) and proteins detected as described above with
AP secondary antibodies.
Analysis of DNA synthesisCell culture and proliferation
SMCs were plated in 24 well plates in F12/FCS, in-SMCs were isolated from the aorta of adult Sprague
Dawley rats by digestion with 0.1% collagenase.32 The cubated for 24 h, and thereafter serum-starved for 72 h
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Table 1. Effects of fucoidan and heparin on proliferation of smoothin F-12/BSA. The cells were incubated with growth
muscle cells cultured in the presence of 10% FCS.factors with or without addition of heparin or fucoidan
Treatment Times (h) Mean SDin F12/BSA together with 3H-thymidine (1 Ci/ml)
for an additional 24 h, washed three times with PBS
0.1% BSA (initial cellon ice, and incubated overnight in 10% trichloroacetic number) 0 5200 710
acid (TCA). The cells were washed three times with 10% FCS 23000 1760
TCA, solubilised in 0.1 M NaOH for 60 min, and radio- 10% FCS + 100 g/ml
fucoidan 48 10600 1260activity measured by liquid scintillation counting.
10% FCS + 100 g/ml
heparin 15700 1590
10% FCS 43600 3330
10% FCS + 100 g/mlElectron microscopy
fucoidan 98 11900 1130
10% FCS + 100 g/ml
To estimate the influence of fucoidan on SMC mor- heparin 25500 2770
phology, the cells were cultured in 60 mm Petri dishes 10% FCS 68100 2440
and incubated in F12/FCS with or without heparin or 10% FCS + 100 g/ml
fucoidan 144 11400 1010fucoidan. The cells were fixed with 3% glutaraldehyde
10% FCS + 100 g/mlin 0.1 M sodium cacodylate-HCl buffer (pH 7.3) with heparin 29700 2450
0.05 M sucrose for 1 h, scraped off the Petri dishes,
Cells were seeded in 12-well dishes in F12/FCS, cultured for 24 h,and transferred to plastic tubes. The specimens were
transferred to F12/BSA, incubated for 72 h. Thereafter, FCS andpostfixed in 1% osmium tetroxide in 0.1 M sodium drugs were added and the number of cells were counted after the
cacodylate-HCl buffer (pH 7.3) with 0.5% potassium indicated times. The results are given as mean values (n=36).
The differences in cell numbers between control and drug treatedferrocyanate for 1 h at 4 °C, dehydrated in ethanol,
cultures at the different times were statistically significant (p<0.001).stained in 2% uranyl acetate in ethanol, and embedded
in low-viscosity epoxy resin. Thin sections were cut
on an LKB Ultrotome IV, stained with lead citrate synthesis experiments were performed with quad-
and examined in a Philips CM 120 Twin electron ruplicate samples and each experiment repeated three
microscope. times. Data from three experiments were pooled and
evaluated by ANOVA analysis followed by Newman–
Keuls post-hoc tests. A significant difference was con-
sidered to exist with p values equal to or less thanImmunofluorescence microscopy
0.05. Immunoblotting and immunohistochemistry ex-
periments were performed three times and rep-SMCs were seeded on glass coverslips and cultured
resentative results from one experiment are shown.as indicated before. The cells were stimulated for
different time intervals with 10% FCS together with
100 g/ml fucoidan or heparin and fixed in 4% form-
aldehyde in PBS for 1 h at room temperature. The Results
specimens were then washed with PBS and per-
meabilised in 0.1% Triton×100. After rinsing in PBS, Effect of fucoidan and heparin on SMC proliferation
the cells were incubated in 0.15 M glycine for 15 min,
followed by incubation for 30 min in 3% BSA in PBS. To determine the anti-proliferative activity, we counted
The specimens were then exposed to pMAPKp anti- SMCs grown in F12/FCS with or without 100 g/ml
bodies (1:200) overnight at 4 °C, followed by detection fucoidan or heparin at various time points. Fucoidan
with FITC-labelled secondary antibodies (1:50) for 1 h appeared to be a more potent inhibitor of SMC pro-
at room temperature. The primary and secondary liferation than heparin and totally blocked the increase
antibodies were diluted in PBS with 0.1% BSA. The in cell number (Table 1). We also measured DNA
specimens were mounted in Vectashield and studied synthesis in growth-arrested SMCs stimulated with
in a Nikon fluorescence microscope. 10% FCS in the presence of increasing concentrations
of fucoidan or heparin. Inhibition of DNA replication
by both substances was dose-dependent. At 100 and
500 g/ml the inhibitory effect of fucoidan was sig-Data analysis
nificantly higher than that of heparin (p<0.05 and
p<0.01, respectively; Table 2a). In order to excludeAnalysis of SMC proliferation was performed with 12
samples in each group and repeated three times. DNA non-specific toxic effects of fucoidan and heparin, cell
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Table 2. Effects of fucoidan and heparin on DNA synthesis in smooth muscle cells cultured in the presence of different mitogens.
Mitogen
Treatment 10% FCS 10 ng/ml 20 ng/ml 20 ng/ml 200 nM
PDGF-BB bFGF hbEGF AT II
(A) (B) (C) (D) (E)
0.1% BSA 5 18 39 45 46
Mitogen (Control) 100 100 100 100 100
Mitogen + 1 g/ml fucoidan 105 73 66 146 85
Mitogen + 1 g/ml heparin 98 84 167 122 115
Mitogen + 5 g/ml fucoidan 94 91 187 123 86
Mitogen + 5 g/ml heparin 94 73 130 133 89
Mitogen + 10 g/ml fucoidan 72 101 177 101 79
Mitogen + 10 g/ml heparin 92 80 257 91 84
Mitogen + 50 g/ml fucoidan 55 56 145 92∗∗ 63
Mitogen + 50 g/ml heparin 56 79 204 58 62
Mitogen + 100 g/ml fucoidan 38∗ 22∗∗∗ 153 96∗ 60
Mitogen + 100 g/ml heparin 49 83 209 65 58
Mitogen + 500 g/ml fucoidan 19∗∗ 5∗∗∗ 25∗∗∗ 46 43
Mitogen + 500 g/ml heparin 44 74 197 48 44
Inhibitory effects of heparin and fucoidan on DNA synthesis in SMCs induced by 10% FCS (A), 10 ng/ml PDGF-BB (B), 20 ng/ml bFGF
(C), 20 ng/ml hbEGF (D), and 200 nM AT II (E). SMC cultures were serum starved for 72 h, stimulated with the different mitogens in the
presence of increasing concentrations of heparin or fucoidan together with 3H-thymidine for 24 h. DNA synthesis was determined by
scintillation counting as described in Materials and Methods.
The effect of heparin and fucoidan is expressed as percentage of control and was calculated from the following relationship: percentage
control of DNA synthesis=(stimulation of DNA synthesis in the presence of inhibitor/stimulation of DNA synthesis in controls)×100%.
Statistical comparison between the same dose of fucoidan and heparin (∗=p<0.05; ∗∗=p<0.01; ∗∗∗=p<0.001).
Fetal calf serum (FCS), platelet-derived growth factor BB (PDGF BB), basic fibroblast growth factor (bFGF), heparin-binding epidermal
growth factor (hbEGF), and angiotensin II (AT II).
cultures were studied by phase contrast- and electron Inhibition of MAPK activity by fucoidan or heparin
microscopy. We did not detect any major differences
in cell morphology between control cells and cells MAPK activation by different growth factors was ana-
lysed by Western blotting with antibodies specific fortreated with 0.1–1 mg/ml fucoidan or heparin.
Growth-arrested SMCs were also exposed to 10 ng/ phosphorylated MAPK (pMAPK). SMCs were stim-
ulated for different time intervals by 10% FCS in theml PDGF-BB, 20 ng/ml bFGF, 20 ng/ml hbEGF, and
200 nM AT II with or without fucoidan or heparin presence or absence of 100 g/ml fucoidan or heparin.
FCS increased MAPK phosphorylation with a peakand DNA synthesis analysed. PDGF-BB was the most
potent mitogen and increased DNA synthesis 6–8- after 10–15 min and both fucoidan and heparin re-
duced pMAPK levels, although fucoidan caused afold; whereas the other factors showed a 1.5–2.5-fold
stimulation. In the presence of PDGF-BB, 100 and stronger inhibition (Fig. 1A). Similar results were ob-
tained with two different antibodies against pMAPK.500 g/ml fucoidan inhibited DNA synthesis almost
completely, whereas heparin lacked effect at these We also studied the effect of 100 g/ml fucoidan and
heparin on MAPK phosphorylation in SMCs stimulatedconcentrations (p<0.001; Table 2b). Both poly-
saccharides enhanced bFGF-induced DNA replication. with the previously described growth factors. All of them
increased MAPK phosphorylation with a maximum afterHowever, at 500 g/ml, fucoidan had an inhibitory
effect whereas heparin still was stimulatory (p<0.001; 15–30 min, but hbEGF, bFGF and AT II were less effective
in enhancing pMAPK levels than FCS and PDGF-BB.Table 2c). We observed a variation in the action of the
polysaccharides in SMCs stimulated by hbEGF. At Fucoidan attenuated MAPK phosphorylation induced
by PDGF-BB and AT II. Heparin decreased MAPK phos-concentrations of 1 and 5 g/ml, fucoidan and heparin
stimulated induction of DNA synthesis (p<0.01), phorylation following treatment with hbEGF and AT II.
However, in SMCs stimulated by PDGF-BB, pMAPKwhereas heparin at 50–500 g/ml and fucoidan at
500 g/ml were inhibitory (Table 2d). Both poly- levels were higher after 30–60 min with heparin than
with fucoidan. Both substances enhanced pMAPK levelssaccharides reduced the DNA replicative response in
cells stimulated by AT II (Table 2e). in cells stimulated by bFGF (Fig. 1B–E).
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Fig. 1. Immunoblotting analysis of pMAPK expression in SMCs stimulated with 10% FCS (A), 10 ng/ml PDGF-BB (B), 20 ng/ml bFGF
(C), 20 ng/ml hbEGF (D), and 200 nM AT II (E) in the presence or absence of 100 g/ml fucoidan or heparin. SMC cultures were serum-
starved for 72 h, stimulated with the different mitogens for 0, 10, 15, 30, and 60 min and proteins isolated for immunoblotting analysis
using antibodies against phosphorylated (pMAPK) or total MAPK content (MAPK) as described in Materials and Methods. Representative
immunoblots from three experiments are shown.
hyperplasia in vivo.14 Similar properties have beenInhibition of nuclear MAPK translocation by fucoidan
attributed to other polysulphated polysaccharidesand heparin
such as pentosan polysulphate and fucoidan.14,33 In
contrast to heparin, the mechanisms responsible forTo investigate if fucoidan prevents nuclear trans-
the growth inhibitory effects of these compounds havelocation of MAPK, we studied the localisation of
not previously been examined in detail.pMAPK in SMCs by immunocytochemistry. Cells were
Here, we provide evidence that fucoidan decreasesstimulated for 15, 30 and 60 min with FCS in the
SMC proliferation and DNA synthesis induced bypresence or absence of fucoidan or heparin. Im-
serum and purified growth factors that act eithermunoreactivity in the nucleus was increased after
through receptor tyrosine kinases or G protein-coupled15 min and reached a maximum after 30 min. Nuclear
receptors. Fucoidan was found to be a more potentpMAPK staining was prevented in cells stimulated
inhibitor of DNA synthesis than heparin in SMCswith FCS for 30 min in the presence of 100 g/ml
stimulated by FCS, PDGF-BB, hbEGF, and AT II. Espe-fucoidan or heparin (Fig. 2). After 60 min the inhibitory
cially at higher doses, the effect of fucoidan was moreactivity of fucoidan and heparin was decreased.
pronounced, and in cells stimulated with PDGF-BB
fucoidan inhibited DNA synthesis whereas heparin
was without effect. Also with respect to molarity,
Discussion fucoidan was more effective than heparin, since the
approximate molecular weight of fucoidan is higher
Heparin has been shown to inhibit SMC proliferation than that of heparin. This may be due to differences
in the degree of sulfation, a factor previously shownboth in vitro and during the formation of intimal
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Fig. 2. Immunocytochemical analysis of pMAPK localization in SMCs by immunocytochemistry. Serum-starved SMC cultures (A; Control)
were stimulated with FCS (B) in the presence of 100 g/ml fucoidan (C) or heparin (D) for 30 min and the samples prepared for
immunocytochemistry using antibodies against pMAPK as described in Materials and Methods. A reduced nuclear pMAPK staining is
evident in cells treated with fucoidan and heparin. Fetal calf serum (FCS), platelet-derived growth factor BB (PDGF BB), basic fibroblast
growth factor (bFGF), heparin-binding epidermal growth factor (hbEGF), and angiotensin II (AT II).
to determine the anti-proliferative activity of both since inhibitors of the upstream activator of p42/
44, MEKK-1, also reduce DNA synthesis induced bypolysaccharides in addition to the length of the poly-
saccharide chain.30,34,35 Commercially available fuc- various mitogens.23,39–41 In addition, control of ERK
activity has also been suggested to be involved inoidan from the marine brown algae Fucus vesiculosus
(the preparation used in this study) is a polymer of - the growth factor dependent development of intimal
hyperplasia39,42 but not JNK and p38, which seem to1-3 L-fucose with only O-sulfated groups at C-4.26
Desulfation of fucoidan has been shown to decrease be involved in cell activation during inflammation and
stress response.43 Our experiments show that fucoidanits anti-proliferative activity28,34 and 30 sugar units
have been demonstrated to be required in order for and heparin influence phosphorylation and activation
of MAPK in SMCs stimulated with growth factors.fucoidan to retain its anti-proliferative activity.30
To examine the possible mechanisms responsible for Fucoidan reduced the expression of pMAPK in cells
stimulated with FCS and AT II in a similar manner asthe anti-proliferative effect of fucoidan, we analysed
the ability of the polysaccharides to interfere with heparin. In contrast to heparin, fucoidan also reduced
pMAPK levels in SMCs stimulated with PDGF-BB. Ingrowth factor-mediated MAPK signalling. The MAPK
family of protein kinases is essential for both SMC agreement with these findings, heparin was previously
found to lack inhibitory effect on MAPK activationmigration and proliferation. MAPKs transduce signals
from different growth factor receptors and the in- and DNA-synthesis in SMCs stimulated by PDGF-BB,
and it has been suggested that heparin rather inhibitsvolvement of this pathway in the control of cell cycle
progression is well documented.18 MAPK activity MAPK signalling elicited by G-protein coupled re-
ceptors such as the AT II receptor.21,23,24 Recently, EGFthrough (ERK) p42/44 provides a link between cell
surface receptors and the nucleus since activated p42/ receptor transactivation after stimulation of G-protein
coupled receptors was shown to be dependent on44 are translocated to the nucleus where transcription
factors are targeted and cell cycle progression me- proteolytic cleavage of membrane-bound hbEGF, and
possibly this is relevant for the antiproliferative effectdiated.36–38 Also in SMCs, ERKs have been suggested
to be important mediators of growth factor signalling of heparin.44
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